KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash & Current Investments: 2016-2024

Historic Cash & Current Investments for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $110.6 million.

  • Amneal Pharmaceuticals' Cash & Current Investments rose 171.94% to $201.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $442.5 million, marking a year-over-year increase of 72.97%. This contributed to the annual value of $110.6 million for FY2024, which is 20.77% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' Cash & Current Investments stood at $110.6 million, which was up 20.77% from $91.5 million recorded in FY2023.
  • Amneal Pharmaceuticals' Cash & Current Investments' 5-year high stood at $341.4 million during FY2020, with a 5-year trough of $26.0 million in FY2022.
  • In the last 3 years, Amneal Pharmaceuticals' Cash & Current Investments had a median value of $91.5 million in 2023 and averaged $76.0 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 89.52% in 2022, then soared by 252.41% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Cash & Current Investments stood at $341.4 million in 2020, then dropped by 27.41% to $247.8 million in 2021, then crashed by 89.52% to $26.0 million in 2022, then surged by 252.41% to $91.5 million in 2023, then grew by 20.77% to $110.6 million in 2024.